1. Home
  2. AKTX vs PRSO Comparison

AKTX vs PRSO Comparison

Compare AKTX & PRSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.23

Market Cap

9.1M

Sector

Health Care

ML Signal

HOLD

Logo Peraso Inc.

PRSO

Peraso Inc.

HOLD

Current Price

$0.82

Market Cap

8.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKTX
PRSO
Founded
N/A
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
8.5M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
AKTX
PRSO
Price
$0.23
$0.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$2.53
$3.00
AVG Volume (30 Days)
363.5K
521.6K
Earning Date
11-13-2025
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$13,001,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$35.76
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.15
52 Week Low
$0.22
$0.52
52 Week High
$1.73
$2.37

Technical Indicators

Market Signals
Indicator
AKTX
PRSO
Relative Strength Index (RSI) 32.15 37.06
Support Level $0.22 $0.91
Resistance Level $0.25 $0.92
Average True Range (ATR) 0.02 0.09
MACD 0.00 -0.02
Stochastic Oscillator 12.55 2.15

Price Performance

Historical Comparison
AKTX
PRSO

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.

Share on Social Networks: